RE:Rare Disease Report(4050 IPF partnership completed, all that’s left is the NR announcement)
“PBI-4050 is now entering pivotal placebo-controlled phase 3 clinical trials for the treatment of idiopathic pulmonary fibrosis (IPF) and has already begun placebo-controlled phase 2 trials in metabolic syndrome and type 2 diabetes patients.”